Introduction
============

Obesity is a major contributor to the global burden of chronic disease, such as type 2 diabetes.^[@bib1]^ A strong genetic impact on obesity has been established. However, the identification of specific genes involved in common forms of human obesity has proven elusive, despite great efforts made through different approaches, including candidate gene studies, genome-wide linkage and genome-wide association (GWA) studies.^[@bib2],\ [@bib3]^ So far, GWA studies have identified around 50 obesity-associated genetic loci. However, these loci together explain only about 1--2% of body mass index (BMI) variations in the studied populations.^[@bib4]^ Therefore a major question is how the remaining so called 'missing\' heritability can be explained.^[@bib5]^ There are two principal concerns about the interpretation of GWA results. First, the approach is based on the common disease, common variant hypothesis. The commercial single-nucleotide polymorphism (SNP) arrays used in GWA studies were designed to cover the common genetic variants (minor allele frequency (MAF) \>5% in populations). Therefore rare variants could not be directly evaluated using such arrays. Second, imperfect statistical models, which do not account for gene--gene and gene--environment interactions, were used in GWA data analyses.^[@bib6]^

Recently developed high-throughput sequencing technology complements SNP arrays and shows power to detect rare disease-causing variants by deep sequencing of all known exons.^[@bib7],\ [@bib8],\ [@bib9]^ This revolution of technology holds promise to elucidate complex diseases by allowing a genome-wide search for low frequency and rare and putatively functional variants. Exome sequencing might be most efficient when applied to patients with more extreme forms of common diseases, such as morbid obesity; first, it increases the chances to obtain significant association for rare variants with high penetrance; second, genetic variants in the protein coding sequence might be more likely to have a strong impact on the phenotype than variants in intergenic regions.

In this study, we employed exome sequencing to detect low frequency and rare gene variants enriched in adult subjects with morbid obesity and validated them against never-obese elderly adults. We reasoned that in this way we would enrich for obesity genes among cases and filtered away such genes in the controls. Here we report a low-frequency obesity-associated variant in the coding region of the synaptophysin-like 2 (*SYPL2*) gene.

Subjects and methods
====================

Sample selection
----------------

The cohorts for genetic studies are described in [Table 1](#tbl1){ref-type="table"}. Subjects were recruited by local advertisement for the purpose of studying genes regulating body weight or in association with planned visits to our medical or surgical units for morbid obesity or scoliosis, respectively. Most of them have been described.^[@bib10],\ [@bib11]^ From the obese subset, we selected, among the 10% with the highest BMI, 100 subjects with extreme obesity for exome sequencing (69 women, 31 men, age 41.5±11.5 years, BMI 52.2±3.8 kg/m^2^). All selected subjects had morbid obesity defined as BMI\>40 kg/m^2^. As controls for the exome sequencing, we used subjects already collected for an ongoing genetic study on idiopathic scoliosis (76 women, 24 men, age 24.5±12.8 years, BMI 21.9±4.3 kg/m^2^). For the first genotyping validation, we selected the 494 morbidly obese subjects with the highest BMI in the large sample collection described above, including the 100 subjects who had been used for exome sequencing. As controls, we used 496 never-obese subjects with age \>40 years and BMI \<30 kg/m^2^. In the second confirmation, we genotyped remaining 1425 morbidly obese subjects and 782 never-obese controls with age \>40 years and BMI\<30 kg/m^2^.

The non-obese controls for exome sequencing had scoliosis. Otherwise all other control subjects were healthy according to self-report. There was an overrepresentation of women in the studied cohorts. Obese women are more likely to search medical advice for their obesity. Scoliosis is more common among women. Subjects were of European ancestry and living in Sweden. The study was approved by the local Ethics Committees, and all subjects gave their informed consent to participation.

DNA preparation and pooling
---------------------------

Genomic DNA was prepared from PBMCs using the QiAmp DNA blood Maxi kit (cat no. 51194, Qiagen, Hilden, Germany). DNA purity and quality was confirmed by A260/280 ratio \>1.8 on Nanodrop (Thermo Fisher Scientific Inc., Waltham, MA, USA) and agarose gel electrophoresis. DNA concentration was measured by Qubit (Life Technologies, Stockholm, Sweden). Subsequently, we took 0.8 *μ*g of each DNA sample and randomly divided them into 10 pools, each containing 10 samples of either obese cases or controls. The concentrations of pooled DNA samples were measured with Qubit, and the samples were run on agarose gel.

Exome sequencing
----------------

Exome sequencing was performed at the Science for Life Laboratory (SciLifeLab), Stockholm, Sweden. Each DNA library was prepared from 3 *μ*g of the pooled genomic DNA. DNA was sheared to 300 bp using a Covaris S2 instrument and enriched by using the SureSelectXT Human All Exon 50 Mb kit and an Agilent NGS workstation according to the manufacturer\'s instructions (SureSelectXT Automated Target Enrichment for Illumina Paired-End Multiplexed Sequencing, version A, Agilent Technologies, Santa Clara, CA, USA).

The clustering was performed on a cBot cluster generation system using a HiSeq paired-end read cluster generation kit according to the manufacturer\'s instructions (Illumina, San Diego, CA, USA). The samples were sequenced on an Illumina HiSeq 2000 as paired-end reads to 100 bp/read (Illumina). All lanes were spiked with 1% phiX control library, except for lane 8, which had 2% phiX. The sequencing runs were performed according to the manufacturer\'s instructions. Base conversion was done using Illumina\'s OLB v1.9 (Illumina).

Sequencing read mapping, variant calling and functional annotation
------------------------------------------------------------------

Sequencing reads were aligned to the current human reference sequence (assembly hg19, NCBI build 37) (<http://hgdownload.soe.ucsc.edu/goldenPath/hg19/chromosomes/>) by using Burrows-Wheeler Aligner (BWA version 0.6.1, <http://bio-bwa.sourceforge.net/>, Li and Durbin^[@bib12]^) with a read trimming parameter --*q* of 20. Sequence variants were called by using the multi-way pileup function of samtools-0.1.18 (<http://samtools.sourceforge.net/>), with a minimum mapping quality of 20 and minimum read depth of 5 × for filtering. PCR duplicates were removed using samtools prior to variant calling. For functional annotation of sequence variants, we employed annovar (<http://www.openbioinformatics.org/annovar/>, Wang *et al*^[@bib13]^) to integrate information from a variety of databases in public domains, such as gene reference (<http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/refGene.txt>, 2013), dbSNPs (SNP135, <http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/snp137.txt.gz>) and the 1000 Genome project (<http://www.1000genomes.org/>).

Variant filtering and enriching for obesity
-------------------------------------------

We used the following filtering criteria to select low-frequency and rare single-nucleotide variants (SNVs) from exome sequencing data. Those SNVs enriched in morbidly obese subjects were taken forward for validation ([Figure 1](#fig1){ref-type="fig"}). First, we filtered for variants with a depth of 5 × and mapping quality (MQ) ≥20. Then we looked for putatively functional variants, that is, variants from exonic regions, splicing sites or 5′ upstream regions. In the next step, we compared the occurrences of a variant between obese and control pools. Only variants called in ≥2 obese pools, but with no call or called once in control pools, were used in the further filtering step; this step was applied to avoid potential false-positive variants. The last filtering was based on allele frequency. We looked for low-frequency and rare SNVs, that is, variants that were not found in public databases or known SNPs with a MAF≤5% in general populations (1000 Genomes project 2011 May release).

Variant validation by genotyping
--------------------------------

Variant validation was focused on SNVs enriched by the above filtering steps that could fit into a manageable genotyping panel and was carried out in two steps. First, all selected variants were genotyped in 494 obese subjects and 496 controls ([Table 1](#tbl1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}) using the Illumina GoldenGate assay performed at the SNP/SEQ Technology Platform at Uppsala University, Sweden (<http://www.molmed.medsci.uu.se/SNP+SEQ+Technology+Platform/Genotyping/>, Fan *et al*^[@bib14]^). Secondly, genotyped variants showing nominal significant association with obesity were genotyped in an additional 1425 obese and 782 controls. Genotyping was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (SEQUENOM, Agena Bioscience, San Diego, CA, USA) at the Mutation Analysis core Facility (MAF) at Karolinska Institutet, Sweden.^[@bib15]^ Multiplexed assays were designed using the MassARRAY Assay Design v4.0 Software (Agena Bioscience). Protocol for allele-specific base extension was performed according to Agena Bioscience\'s recommendation. All genetic association results in validation cohorts 1 and 2 have been submitted to GWAS Central.

Statistical analysis of association
-----------------------------------

Subjects were characterized by BMI, and values are reported as mean±SD for obese and controls separately. Genetic association analysis and odds ratio calculation were performed using PLINK (<http://pngu.mgh.harvard.edu/~purcell/plink/>, Purcell *et al*^[@bib16]^). Hardy--Weinberg equilibrium (HWE) of the genotype frequencies among cases and controls were checked separately for each run of validations prior to association analysis. A HWE nominal *P*-value of 0.01 in controls was used as a cutoff for exclusion of variants from further analysis. BMI was analyzed using standard linear regression implemented in PLINK. Sex and age were used as covariates to evaluate their influence on the association of a variant with BMI.

Results
=======

Discovery of rare variants by exome sequencing
----------------------------------------------

To identify potential functional low-frequency and rare variants associated with extreme obesity, we performed exome sequencing on pooled DNA from 100 subjects (10 pools) with severe morbid obesity and 100 control subjects (10 pools). Thus there was DNA from 10 subjects in each pool. The characteristics of subjects for the exome sequencing are shown in [Table 1](#tbl1){ref-type="table"}. The obese subjects were older than the controls, whereas the gender distribution was similar between cohorts, with an overrepresentation of women. In total, we obtained \>100 million reads from each pool ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). After trimming low-quality reads and removing PCR duplicates, 95% of reads were mapped to the current human genome reference (assembly hg19, NCBI build 37) except for one control pool that had a little lower mapping rate. The vast majority of reads were uniquely mapped on the same chromosome for both paired reads. Discordance between paired reads was rare. Reads were paired with higher rates (97%) in obese pools than in control pools (80--95%) ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). More than 92% of target regions were covered by 5 × reads, and \>80% of target regions were covered by 30 × reads ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

Potentially interesting variants were identified through several filtering steps ([Figure 1](#fig1){ref-type="fig"}). All variants were called using a depth of 5 × and MQ≥20  as the first filtering criteria. In total, we got 114 034--190 130 variants from each of the 20 pools. About 95% of variants were known SNPs, that is, SNPs with rs numbers. The majority of variants were located in exons, introns or intergenic regions, whereas others were in nearby slicing sites or in regulatory regions ([Table 2](#tbl2){ref-type="table"}). We focused on putatively functional variants, that is, variants from exonic regions (excluding synonymous variants), splicing sites or 5′ upstream. We obtained 31 520 such variants in obese pools and 26 565 in non-obese pools. Those variants were found in at least one obese pool or control pool, respectively. In all, 20 652 (65.5%) potentially functional variants were present in both obese and control pools, and 10 868 (34.5%) were singletons for obesity. Next we looked for variants appearing more often in obese pools. At this step, there were 5788 variants left, and they were detected in ≥2 obese pools but did not appear or appeared just once in control pools. Finally we filtered for low-frequency and rare SNVs, that is, SNVs that were not found in public databases or SNPs with a MAF≤5% in general populations (1000 Genome project, <http://www.1000genomes.org/>) were taken forward. With these criteria, 1032 obesity-associated SNVs were obtained.

SNV validation and association analysis
---------------------------------------

From the 1032 SNV, we excluded insertion or deletion variants to avoid potential technical difficulties in genotyping. Then we filtered for SNVs shared by at least two obese pools with the highest yield. After manually checking alignments of reads carrying the variants by using the IGV software (<http://www.broadinstitute.org/igv/>) to exclude potential artifacts, we selected 144 SNVs for genotyping (142 dbSNP and 2 unknown SNVs). Sequencing depths and numbers of shared obesity pools of the 144 SNVs are shown in [Supplementary Table S3](#sup1){ref-type="supplementary-material"}. Most SNVs were found in two (83) or three (31) pools. Ten SNVs had difficulties in primer design for genotyping and were replaced with singleton SNVs.

SNV validations were divided into two steps. First, the 144 SNVs were genotyped in 494 morbidly obese subjects, including the 100 exome-sequenced obese subjects, and 496 non-obese controls ([Table 1](#tbl1){ref-type="table"}). Genotyping of 20 SNVs failed. The average per SNV call rate for the remaining 124 SNVs was 97.95%. The concordance rate of MAFs estimated from exome sequencing data and the MAF based on genotype results was 0.83 ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Among the successfully genotyped SNVs, 21 were monomorphic. The remaining 103 variants were used for association analysis. HWE was checked prior to association analysis. After removal of 5 additional SNVs due to an HWE *P*-value\<0.01, 98 SNVs were used in further association analysis.

Five out of the 98 SNVs showed significant allelic association with obesity with a nominal *P*-value 0.05 ([Table 3](#tbl3){ref-type="table"}, [Supplementary Table S4](#sup1){ref-type="supplementary-material"}). These five SNVs were subsequently subjected to the second run of genotyping for confirmation in a large case--control cohort consisting of 1425 morbidly obese subjects and 782 never-obese controls. Only one SNV, rs62623713 (NM_001040709:c.A296G:p.E99G), consistently displayed a significant association with obesity ([Table 3](#tbl3){ref-type="table"}). However, in the final joint analysis of all genotyped subjects two SNVs, rs62623713 and rs35923425 (NM_024727:c.G1134C:p.L378F), showed nominally significant association with obesity in 1917 morbid obese and 1278 never-obese controls, with a *P*-value of 0.0063 (odd ratio (OR)=1.32, MAF 0.081 in obese and 0.063 in controls) or a *P*-value of 0.004 (OR=1.35, MAF 0.076 in obese, 0.058 in controls), respectively ([Table 3](#tbl3){ref-type="table"}). rs62623713 located at 110 019 439 base pair (bp) on chromosome 1 (hg19) is a missense variant in exon 4 of the *SYPL2* gene. rs35923425 located at 169 569 432 bp on chromosome 3 is also a missense variant in exon 7 of the leucine-rich repeat containing 31 (*LRRC31*) gene.

By quantitative trait analysis in all genotyped subjects, rs62623713 showed strong association with BMI assuming an additive genetic model (beta 2.13, *P*-value of 6.28 × 10^−5^, [Table 4](#tbl4){ref-type="table"}). The variant explained 0.5% BMI variation in genotyped subjects. Homozygous subjects for the rs62623713\*G allele had higher BMI (mean=45.56 kg/m^2^) when compared with subjects who were heterozygous or homozygous for the rs62623713\*A allele ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}). The G allele is overrepresented in our obese subjects (MAF 8%), especially in the homozygous form (12 obese to 2 controls). The same tendency of associations was shown in females (beta 1.99, *P*-value 0.001), males (beta 2.42, *P*-value 0.016), obese subjects (beta 3.39, *P*-value 0.0007) and non-obese subjects (beta 2.16, *P*-value 0.031) ([Table 4](#tbl4){ref-type="table"}). rs35923425 in *LRRC31* was also associated with BMI (beta 1.5, *P*-value 0.60 × 10^−3^). However, significant association was seen in females only.

The significance of associations of 5 SNVs with either obesity or BMI in the first and the final analysis were not influenced when we excluded 100 subjects used in exome sequencing for analyses ([Supplementary Tables S6 and S7](#sup1){ref-type="supplementary-material"}).

To further evaluate any confounding effect of age or gender, we added these variables as covariates in regression models and tested their individual effects separately. rs62623713 maintained strong associations with BMI after adjustment for age or gender ([Supplementary Table S8](#sup1){ref-type="supplementary-material"}). The association between rs35923425 and BMI disappeared after adjustment for age. Furthermore, we also performed a variety of tests to adjust for the analysis of multiple genetic variants. The association of rs62623713 with BMI was still significant with a Bonferroni adjusted *P*-value of 3.0 × 10^−4^ and a genomic-control corrected *P*-value of 0.05. The association of rs35923425 became non-significant with genomic controls, whereas the Bonferroni corrected *P*-value was 0.029 ([Supplementary Table S9](#sup1){ref-type="supplementary-material"}).

Discussion
==========

Using exome sequencing followed by large-scale genotyping, we identified a low-frequency coding variant, rs62623713 (E99G) in exon 4 of the *SYPL2* gene, consistently showing association with morbid obesity. rs62623713 has a MAF of 2.9% for the G allele in the general populations according to 1000 Genomes. The variant is overrepresented among our obese subjects (MAF 8%). rs62623713 was not covered by Illumina or Affymetrix genotyping arrays used in previous GWA studies, and no other variants on those arrays was in strong linkage disequilibrium with rs62623713.

To the best of our knowledge there are only three reports of obesity-associated variants detected by exome sequencing.^[@bib9],\ [@bib17],\ [@bib18]^ Albrechtsen *et al*^[@bib17]^ analyzed a cohort with the metabolic syndrome and examined multiple metabolic phenotypes. The study by Huang *et al*^[@bib18]^ primarily analyzed type 2 diabetes. Gill *et al*^[@bib9]^ identified novel *LEPR* variants in severe childhood onset obesity using exome sequencing.

The hypothesis underlying our study is that more severe forms of common obesity might be due to low-frequency or rare variants with a larger impact on the phenotype. A minor portion of morbidly obese cases has been shown to be due to genetic variants with high penetrance. Variants in the melanocortin 4 receptor (*MC4R*) gene explain a few percentage of childhood obesity,^[@bib19]^ and a copy number repeat on chromosome 16^[@bib20]^ has a high penetrance in a few percentages of morbidly obese subjects with cognitive defects. We did not detect any variants in exonic or nearby upstream regions of the *MC4R* in our exome sequencing data, which may be due to the low number of investigated subjects. Our results, that is, the detection of one SNP in *SYPL2* remaining significantly associated with obesity after adjustment for multiple testing, support the notion that low-frequency and rare variants contribute to morbid obesity. However, the present study lacks power to estimate to what extent rare genetic variants cause morbid obesity in the population.

The approach we report using pooled DNA for exome sequencing to get obesity-associated variants, which was followed by genotype validation, is a cost-effective method. Our study has its limitations. We did not have access to a reliable family history of our patients and therefore do not know whether their obesity displays patterns of monogenic inheritance. On the other hand, as obesity is common, pedigree information might be difficult to interpret due to heterogeneity, that is, different causes of obesity in different family members. We only genotyped validated variants detected in more than one sequencing pools to limit the number of false positives. Although by genotyping variants detected in one sequencing pool only we might have discovered additional rare obesity-associated variants, we did not apply this strategy because of lower sequencing overage in some regions and risk of false-positive variants. However, with the applied strategy we were able to detect true low-frequency SNVs (about 30% of SNVs with a MAF≤0.05 and \>60% with a MAF≤0.10) in obese pools. Estimated MAFs in exome sequencing data correlated with those based on individual sample genotyping ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). In our study, failure in validation by genotyping seemed not due to low depth as major failed SNVs had an average depth ≥20 × ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Imperfect primer designs in multiplex genotyping could be a major cause of genotyping failure.

*SYPL2* (also called *MG29*) is expressed in the adipose tissue, brain, kidney, heart and cerebellum. Functionally, the SYPL2 protein has been proposed to participate in cellular calcium ion homeostasis.^[@bib21]^ The protein is expected to be involved in transporter activity and to localize in various compartments, such as synaptic vesicle.^[@bib22]^ Interestingly, mice lacking *Sypl2/Mg29* exhibit reduced body weight, abnormal skeletal muscle membranes and irregular skeletal muscle contractility.^[@bib23]^ How the gene might influence adipose tissue formation and its potential role in obesity development is unclear and needs further investigation, which is beyond the scope of this study.

In previous reports, *SYPL2* was associated with major depressive disorder in European population.^[@bib24]^ An association between obesity and depression has repeatedly been established. In a meta-analysis, obesity was found to increase the risk of depression. In addition, depression was found to be predictive of obesity.^[@bib25]^ Another study found that the association of obesity with depression was mainly confined to persons with severe obesity.^[@bib26]^

*SYPL2* belongs to the synaptophysin family. Synaptophysin regulates activity-dependent synapse formation in cultured hippocampal neurons,^[@bib27]^ and it is required for kinetically efficient endocytosis of synaptic vesicles in cultured hippocampal neurons.^[@bib28]^ Food intake is subject to a complex regulation by the hypothalamus and other brain centers, including the brain stem and the hippocampus. Thus one could hypothesize that *SYPL2* is involved in the central regulation of food intake possibly affecting the central reward systems and the hedonic effects of food.

In conclusion, we identified a low-frequency obesity-associated coding variant in the *SYPL2* gene using exome sequencing with pooled DNA from 100 morbidly obese and 100 non-obese subjects, which was followed by genotype validation in 3197 case--control subjects. Our results provide evidence of the existence of a coding variant associated with obesity although further functional studies of this genetic variant remain to be performed.
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###### Clinical information on samples used for exome sequencing and variant validation

                                   *Obese cases*   *Controls*                                                         
  ------------------------------- --------------- ------------ ---------- ----------- --------- ---------- ---------- -----------
  Discovery by exome sequencing       Swedish        69/31     52.2±3.8   41.5±11.5    Swedish    76/24    21.9±4.3   24.5±12.8
  First validation                    Swedish       357/137    51.1±3.7   40.9±11.6    Swedish   351/145   24.4±2.7   55.1±5.8
  Second confirmation                 Swedish       1068/357   43.1±2.5   42.3±11.6    Swedish    696/86   23.8±2.9   44.3±4.4
  Total                                             1494/525                                     1123/255              

Values for BMI and age are mean±SD. Controls used in the first validation and second confirmation were non-obese.

###### Summary of variants with at least 5 × depth and MQ \>20 found in pools

  *Genome region*                              *Pool_1*   *Pool_2*   *Pool_3*   *Pool_4*   *Pool_5*   *Pool_6*   *Pool_7*   *Pool_8*   *Pool_9*   *Pool_10*
  -------------------------------------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -----------
  *Obese pools*                                                                                                                                   
   Downstream                                  1041       1509       1031       906        1013       1150       1140       1864       1405       1073
   Exonic                                      22 598     22 619     20 867     22 697     22 622     22 031     22 134     21 244     21 387     22 505
   Exonic;splicing                             339        309        303        341        322        312        311        298        306        324
   Intergenic                                  25 008     18 871     22 830     22 817     25 879     29 673     28 890     30 407     34 951     26 365
   Intronic                                    90 832     110 903    91 629     85 416     93 314     100 064    99 213     122 534    109 572    95 353
   Splicing                                    103        127        113        99         110        100        105        124        107        104
   Upstream                                    1570       3399       1622       1448       1658       1871       1818       4082       2222       1665
   Upstream;downstream                         101        219        121        79         94         107        103        228        132        90
   UTR3                                        4077       6094       4074       3907       4235       4529       4493       6414       5262       4295
   UTR5                                        1523       2737       1511       1394       1510       1643       1617       2931       1776       1522
   UTR5;UTR3                                   4          7          3          4          3          3          5          4          3          3
   Total                                       147 196    166 794    144 104    139 108    150 760    161 483    159 829    190 130    177 123    153 299
                                                                                                                                                   
                                                                                                                                                   
  *Control pools*                                                                                                                                 
  *Genome region*[a](#t2-fn1){ref-type="fn"}                                                                                                      
   Downstream                                  1024       1047       901        1024       721        762        727        612        662        776
   Exonic                                      21 755     20 916     21 605     21 259     20 885     21 415     21 831     21 913     20 981     21 608
   Exonic;splicing                             310        305        312        304        306        312        307        316        300        297
   Intergenic                                  29 501     35 161     28 299     31 790     23 043     27 455     23 063     22 350     22 527     26 235
   Intronic                                    92 012     88 906     83 922     90 250     70 290     74 229     75 347     63 912     69 481     74 572
   Splicing                                    97         98         95         94         88         91         96         88         98         91
   Upstream                                    1628       1546       1398       1654       1120       1170       1159       917        1077       1224
   Upstream;downstream                         94         89         86         91         58         69         64         47         53         65
   UTR3                                        4018       3881       3746       3934       3124       3348       3440       2886       3126       3256
   UTR5                                        1510       1405       1303       1461       1198       1235       1175       990        1147       1220
   UTR5;UTR3                                   3          2          3          2          1          2          2          3          1          4
   Total                                       151 952    153 356    141 670    151 863    120 834    130 088    127 211    114 034    119 453    129 348

Output from annovar. <http://www.openbioinformatics.org/annovar/annovar_gene.html>.

###### Associations of five SNVs with obesity in the first and second runs of validation and in the final analysis

  *CHR*                    *SNP*      *A1*  *Freq_case*   *Freq_control*    *A2*  P-value   *OR*   *L95*   *U95*     *Gene*
  --------------------- ------------ ------ ------------- ---------------- ------ --------- ------ ------- ------- -----------
  *First validation*                                                                                               
   1                     rs62623713    G    0.100         0.077              A    0.044     1.38   1.01    1.88      *SYPL2*
   1                     rs41280330    T    0.017         0.0061             C    0.021     2.88   1.13    7.33      *GNAT2*
   3                     rs35923425    G    0.082         0.050              C    0.0042    1.70   1.18    2.45     *LRRC31*
   14                    rs34106261    A    0.054         0.033              G    0.0184    1.71   1.09    2.67      *RIPK3*
   19                    rs45546534    G    0.061         0.039              A    0.021     1.63   1.07    2.47     *TMPRSS9*
                                                                                                                         
  *Second validation*                                                                                              
   1                     rs62623713    G    0.077         0.054              A    0.0049    1.44   1.12    1.86      *SYPL2*
   1                     rs41280330    T    0.0075        0.0089             C    0.61      0.84   0.43    1.63      *GNAT2*
   3                     rs35923425    G    0.074         0.063              C    0.15      1.19   0.94    1.52     *LRRC31*
   14                    rs34106261    A    0.034         0.038              G    0.57      0.91   0.64    1.28      *RIPK3*
   19                    rs45546534    G    0.044         0.040              A    0.52      1.10   0.82    1.50     *TMPRSS9*
                                                                                                                         
  *Final analysis*                                                                                                 
   1                     rs62623713    G    0.081         0.063              A    0.0063    1.32   1.08    1.61      *SYPL2*
   1                     rs41280330    T    0.0094        0.0079             C    0.51      1.20   0.69    2.08      *GNAT2*
   3                     rs35923425    G    0.076         0.058              C    0.0040    1.35   1.10    1.66     *LRRC31*
   14                    rs34106261    A    0.038         0.035              G    0.58      1.08   0.82    1.44      *RIPK3*
   19                    rs45546534    G    0.047         0.040              A    0.18      1.19   0.92    1.52     *TMPRSS9*

Abbreviations: A1, minor allele (observed allele); A2 alternative allele (reference allele), see [Supplementary Table S3](#sup1){ref-type="supplementary-material"} for more information about SNPs; CHR, chromosome; Freq, frequencies of minor allele A1; OR: odds ratio; L95 and U95, the upper and lower 95% confidence intervals.

###### Quantitative trait analysis with BMI using regression in final validation

  *CHR*              *SNP*      *A1*   *TEST*  *No.*   *Beta*   *L95*   *U95*   P-*value*
  --------------- ------------ ------ -------- ------- -------- ------- ------- -----------
  *Final total*                                                                 
   1               rs62623713    G      ADD    3169    2.13     1.09    3.18    6.28E-05
   1               rs41280330    T      ADD    3177    2.04     −0.82   4.90    0.1626
   3               rs35923425    G      ADD    3174    1.50     0.43    2.58    0.006022
   14              rs34106261    A      ADD    2782    1.09     −0.48   2.66    0.174
   19              rs45546534    G      ADD    3171    0.90     −0.41   2.20    0.1799
                                                                                 
  *Female*                                                                      
   1               rs62623713    G      ADD    2451    1.99     0.79    3.19    0.001182
   1               rs41280330    T      ADD    2457    0.92     −2.36   4.19    0.583
   3               rs35923425    G      ADD    2456    1.63     0.41    2.85    0.00897
   14              rs34106261    A      ADD    2137    0.61     −1.17   2.39    0.5007
   19              rs45546534    G      ADD    2451    0.46     −1.06   1.97    0.5532
                                                                                 
  *Male*                                                                        
   1               rs62623713    G      ADD    718     2.52     0.48    4.57    0.01589
   1               rs41280330    T      ADD    720     6.26     0.53    11.99   0.03253
   3               rs35923425    G      ADD    718     1.00     −1.19   3.18    0.3723
   14              rs34106261    A      ADD    645     2.76     −0.44   5.97    0.09143
   19              rs45546534    G      ADD    720     2.02     −0.51   4.54    0.1176
                                                                                 
  *Lean*                                                                        
   1               rs62623713    G      ADD    1269    0.48     0.05    0.92    0.0307
   1               rs41280330    T      ADD    1270    0.75     −0.43   1.94    0.2125
   3               rs35923425    G      ADD    1271    −0.07    −0.51   0.38    0.7708
   14              rs34106261    A      ADD    1258    −0.01    −0.58   0.57    0.9769
   19              rs45546534    G      ADD    1269    0.13     −0.40   0.66    0.6224
                                                                                 
  *Obese*                                                                       
   1               rs62623713    G      ADD    1900    0.91     0.38    1.43    0.0007152
   1               rs41280330    T      ADD    1907    1.37     −0.08   2.82    0.06345
   3               rs35923425    G      ADD    1903    0.08     −0.46   0.62    0.7744
   14              rs34106261    A      ADD    1524    1.19     0.35    2.04    0.005898
   19              rs45546534    G      ADD    1902    0.04     −0.63   0.71    0.9119

Abbreviations: ADD, the additive effects of allele; A1, observed minor allele; CHR, chromosome; L95 and U95: the upper and lower 95% confidence intervals.
